| Bioactivity | Repirinast (MY-5116) is an orally active anti-allergic agent. Repirinast inhibits histamine release. Repirinast can be used in the research of bronchial asthma[1][2][3]. |
| Invitro | Repirinast inhibits histamine release from rat peritoneal mast cells induced by antigen (IC50: 0.3 μM)[3]. |
| In Vivo | Repirinast (30 mg/kg, i.p.) inhibits antigen-induced early and late pulmonary responses in guinea pigs[1].Repirinast (30 mg/kg, p.o.) inhibits antigen-induced immediate bronchoconstriction in rats[2]. Animal Model: |
| Name | Repirinast |
| CAS | 73080-51-0 |
| Formula | C20H21NO5 |
| Molar Mass | 355.38 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. N Yamada, et al. Repirinast inhibits antigen-induced early and late pulmonary responses and airway hyperresponsiveness in guinea pigs. Int Arch Allergy Immunol. 1993;100(4):367-72. [2]. Takahashi K. Effects of MY-5116 on experimental asthma in rats and guinea pigs. Arerugi. 1986 Oct; 35(10): 1037-46. [3]. M Takei, et al. Inhibition of histamine release from rat peritoneal mast cells by MY-1250, an active metabolite of Repirinast (MY-5116). Int Arch Allergy Appl Immunol. 1990;93(2-3):237-41. |